CL2025003870A1 - Compuestos para el suministro de granulina a través de la barrera hematoencefálica. - Google Patents

Compuestos para el suministro de granulina a través de la barrera hematoencefálica.

Info

Publication number
CL2025003870A1
CL2025003870A1 CL2025003870A CL2025003870A CL2025003870A1 CL 2025003870 A1 CL2025003870 A1 CL 2025003870A1 CL 2025003870 A CL2025003870 A CL 2025003870A CL 2025003870 A CL2025003870 A CL 2025003870A CL 2025003870 A1 CL2025003870 A1 CL 2025003870A1
Authority
CL
Chile
Prior art keywords
compounds
blood
delivery
brain barrier
progranulin
Prior art date
Application number
CL2025003870A
Other languages
English (en)
Inventor
Wang Yaming
Alvarado Alberto
Verdino Petra
H Andrews Forest
Albert Driver David
Edward Fellows Ross
Jean Froning Karen
Scott Girard Daniel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2025003870A1 publication Critical patent/CL2025003870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos para el suministro de progranulina, un fragmento de progranulina, y/o al menos una subunidad de proteína de granulina a través de la barrera hematoencefálica. Compuestos para el suministro de progranulina, un fragmento de progranulina, y/o al menos una subunidad proteica de granulina a través de la barrera hematoencefálica, los compuestos incluyen un dominio de progranulina, un dominio de unión a TfR1, y opcionalmente un dominio de unión a la albúmina. Compuestos para el suministro de progranulina silvestre o no modificada a través de la barrera hematoencefálica.
CL2025003870A 2023-06-21 2025-12-09 Compuestos para el suministro de granulina a través de la barrera hematoencefálica. CL2025003870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363509352P 2023-06-21 2023-06-21

Publications (1)

Publication Number Publication Date
CL2025003870A1 true CL2025003870A1 (es) 2026-03-06

Family

ID=91950485

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003870A CL2025003870A1 (es) 2023-06-21 2025-12-09 Compuestos para el suministro de granulina a través de la barrera hematoencefálica.

Country Status (12)

Country Link
US (1) US20250000992A1 (es)
EP (1) EP4731669A2 (es)
JP (1) JP2025003404A (es)
KR (1) KR20260030123A (es)
AR (1) AR133024A1 (es)
AU (1) AU2024311750A1 (es)
CL (1) CL2025003870A1 (es)
DO (1) DOP2025000323A (es)
IL (1) IL325365A (es)
JO (1) JOP20250317A1 (es)
MX (1) MX2025015276A (es)
WO (1) WO2024263567A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2026075889A1 (en) * 2024-10-04 2026-04-09 Eli Lilly And Company Compositions comprising a progranulin domain for the prevention and treatment of neurodegenerative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000098A2 (pt) * 2016-07-14 2019-04-09 Bioarctic Ab proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
WO2018210898A1 (en) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
BR112021015817A2 (pt) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
PE20240233A1 (es) * 2021-02-02 2024-02-16 Lilly Co Eli Fracciones que prolongan la semivida y metodos de uso de estas
JP2025528797A (ja) * 2022-08-08 2025-09-02 イーライ リリー アンド カンパニー トランスフェリン受容体結合タンパク質及びコンジュゲート
EP4424703A1 (en) * 2023-03-02 2024-09-04 Amylonix AB Polypeptides for transferrin receptor-mediated transcytosis

Also Published As

Publication number Publication date
US20250000992A1 (en) 2025-01-02
WO2024263567A3 (en) 2025-04-03
WO2024263567A2 (en) 2024-12-26
WO2024263567A9 (en) 2025-08-21
AU2024311750A1 (en) 2025-12-18
IL325365A (en) 2026-02-01
MX2025015276A (es) 2026-02-03
JP2025003404A (ja) 2025-01-09
JOP20250317A1 (ar) 2025-12-17
TW202515905A (zh) 2025-04-16
DOP2025000323A (es) 2026-01-30
AR133024A1 (es) 2025-08-20
EP4731669A2 (en) 2026-04-29
KR20260030123A (ko) 2026-03-05

Similar Documents

Publication Publication Date Title
DOP2025000323A (es) Compuestos para el suministro de granulina a través de la barrera hematoencefálica
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
CO2021017433A2 (es) Agonistas del receptor del péptido-1 similar al glucagón
MX2021011997A (es) Enlazadores de conjugacion mejorados.
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
CY1114703T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1s)-1,5-ανυδρο-1-[5-(4-αιθοξυβενζυλ)-2-μεθοξυ-4-μεθυλφαινυλ]-1-θειο-d-γλυκιτολη και μετφορμινη και χρησεις αυτης στη θεραπεια διαβητη
ES2542853T3 (es) Método para tratar miastenia grave
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
CY1111087T1 (el) Παραγωγα 5-(βενζ-(ζ)-υλιδενο)-θειαζολιδιν-4-ονης ως ανοσοκατασταλτικοι παραγοντες
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2022007486A (es) Variantes de progranulina.
ECSP034624A (es) Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
UY27044A1 (es) Combinación de agonistas de gaba e inhibidores de aldosa-reductasa
CL2007001004A1 (es) Compuestos derivados peptidicos, inhibidores de proteasa, utiles para el tratamiento de una infeccion por el virus de la hepatitis c.
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
CL2020002561A1 (es) Composiciones y métodos para el tratamiento de la distrofia macular
Dudek et al. Partial inactivation of the chromatin remodelers SMARCA2 and SMARCA4 in virus-infected cells by caspase-mediated cleavage
CL2022003643A1 (es) Compuestos macrocíclicos y métodos de uso de los mismos.
AR058308A1 (es) Fragmentos vip y metodos de uso de los mismos
ECSP22049014A (es) Variantes de progranulina
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren